Central Nervous System Treatment Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2026-2035)

Global Market Likely to be Driven by Increasing Incidence of Neurological Disorders

The nervous system comprises central nervous system (CNS) (consisting of the brain and the spinal cord) and the peripheral nervous system (consisting of nerves, including the autonomic nervous system, outside of the brain and spinal cord, including those in the arms, legs, and trunk of the body). Together, the brain and the spinal cord act as the main "processing centre" for the entire nervous system, and control all the functions of the body.

Several different medical conditions could affect the nervous system, including degenerative diseases (including Alzheimer’s disease and Parkinson’s disease), blood vessel disorders in the brain (including arteriovenous malformations and cerebral aneurysms), tumours (benign and malignant), disorders of the pituitary gland, demyelinating diseases (such as multiple sclerosis), headaches (including migraines), epilepsy, head injuries like concussions and brain trauma, movement disorders (such as tremors and Parkinson’s disease), neuro-ophthalmologic diseases (vision problems as a result from damage to the optic nerve or its connections to the brain), peripheral nerve diseases (neuropathy), spine disorders, mental disorders (such as schizophrenia), infections (such as meningitis), stroke, etc.

Regulatory Frameworks Looking to Facilitate Development of Personalized Medicine Expected to Drive Market Growth

Central nervous system disorders signify a key area of unmet medical need. Personalized medicine (PM) is a novel concept that seeks to capitalize on known variability in patients, which causes differences in disease susceptibility and response to medication. The European regulatory network seeks to facilitate the development of PM methods for central nervous system disorders, including biomarkers (BMs), companion diagnostics, pharmacogenomics, and rare diseases; new methodologies and innovative clinical trial designs; and advanced treatments and therapies (e.g. gene therapies, somatic cell therapies, and tissue-engineered medicines). Such developments are expected to drive the global central nervous system treatment market. Increased focus on patient centricity and participation of patient groups has led to enhanced regulatory backing, including devoted scientific advice resources, new guidance documents, and multistakeholder platforms to meet challenges in PM development. Such initiatives led to some success (e.g., BM qualification), and there is hope that these would facilitate future approval of personalized central nervous system medicines.

Availability of Treatment Systems and Medical Practitioners Expected to Contribute to Market Growth

Neuroradiology (a branch of neuroscience medicine) seeks to diagnose and treat nervous system problems. Treatments include balloon angioplasty and stenting of carotid or vertebral artery; intra-arterial therapy for stroke; radiation oncology of the brain and spine; endovascular embolization and coiling to treat cerebral aneurysms; kyphoplasty and vertebroplasty to treat vertebral fractures; needle biopsies, spine and soft tissues; etc. Treatment may also include medicines [possibly administered by a drug pump (like those used for people with severe muscle spasms)], deep brain stimulation, spinal cord stimulation, rehabilitation/physical therapy after brain injury or stroke, spinal surgery, etc. Availability of treatment systems, along with that of health care providers, is expected to boost the global central nervous system treatment market. Health care providers from multiple specialties may be required to treat central nervous system related conditions. These may include neurologist, vascular surgeon, neurosurgeon, neuropsychologist, pain physician, psychiatrist, psychologist, radiologist, neuroscientist, nurse practitioners (NPs), physician assistants (PAs), nutritionists or dietitians, primary care doctors, physical therapists, occupational therapists, speech-language therapists, etc.

Global Central Nervous System Treatment Market Segmentation

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global central nervous system treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Teva Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd
• Otsuka Pharmaceutical Co., Ltd.
• Angelini S.p.a.
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.